Drug Trial Radar · NCT06460961
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)
Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Jul 14, 2024
Primary completion
Jul 29, 2026
Study completion Jul 29, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 14, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of MK-6837, administered as a monotherapy and in combination with pembrolizumab (MK-3475), in participants with histologically or cytologically confirmed advanced/metastatic solid tumors that have not responded to conventional therapy. There will not be any hypothesis testing in the study. As of Amendment 04 (effective date: 18-Dec-2025), there are no pharmacokinetic (PK) secondary outcome measures in this study.
Conditions
- Neoplasm Metastasis
Interventions
MK-6837Biological
IV Infusion
PembrolizumabBiological
IV Infusion
Rescue MedicationsDrug
Antihistamine, H2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) administered per product label prior to MK-6837.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants who experience one or more dose-limiting toxicities (DLTs)Time frame: Cycle 1 (Up to approximately 21 days); each cycle is 21 days.
- Number of participants who experience one or more adverse events (AEs)Time frame: Up to approximately 35 months
- Number of participants who discontinue study intervention due to an AETime frame: Up to approximately 35 months
Locations
7 sites in 4 countries. Site status is shown where the registry gives one.
Atlantic Health System Morristown Medical Center ( Site 4001)
Morristown, New Jersey
Providence Portland Medical Center ( Site 4002)
Portland, Oregon
South Texas Accelerated Research Therapeutics (START) ( Site 4003)
San Antonio, Texas
Westmead Hospital ( Site 1002)
Westmead, New South Wales, Australia
The Alfred Hospital ( Site 1001)
Melbourne, Victoria, Australia
Princess Margaret Cancer Centre ( Site 2001)
Toronto, Ontario, Canada
Sheba Medical Center-ONCOLOGY ( Site 3001)
Ramat Gan, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.